Jacobs Levy Equity Management, Inc Nurix Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 229,369 shares of NRIX stock, worth $2.35 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
229,369Holding current value
$2.35 Million% of portfolio
0.02%Shares
9 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$69.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$44.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$42.9 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$39.8 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$30.8 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $483M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...